N-(5-Chloropyridin-2-yl)-5-methoxy-2-nitrobenzamide

We are N-(5-Chloropyridin-2-yl)-5-methoxy-2-nitrobenzamide CAS:280773-16-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N-(5-Chloropyridin-2-yl)-5-methoxy-2-nitrobenzamide
CAS.NO:280773-16-2
Synonyms:N-(5-Chloro-2-pyridinyl)-5-methoxy-2-nitrobenzamide
2-nitro-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide
Molecular Formula:C13H10ClN3O4
Molecular Weight:307.68900
 
Physical and Chemical Properties:
Boiling point:433.598ºC
Flash point:216.033ºC
Index of Refraction:1.657
 
Specification:
Appearance:Yellow powder
Purity:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Betrixaban
 
Note:The product under valid patents will not be offered to the countries covered by patents.
 

N-(5-Chloropyridin-2-yl)-5-methoxy-2-nitrobenzamide


Related News: Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.dimethyl-bis[[methyl(diphenyl)silyl]oxy]silane Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.547-65-9 API and raw material are often confused due to the similar usage of the two terms.2,3,4-Trifluorobromobenzene The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
BIS(4-NITROPHENYL) CARBONATE View Details
Z-Glu(OtBu)-OH View Details
Methyl 5-Formyl-2-methoxybenzoate View Details
3-Amino-4-fluorobenzoic acid manufacturer 1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-one manufacturer ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate,hydrochloride manufacturer N-[3-(Trimethoxysilyl)propyl]ethylenediamine manufacturer Endothelin 1 manufacturer